

Filippo Alongi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5539688/publications.pdf>

Version: 2024-02-01

207
papers

4,886
citations

117453

34
h-index

143772

57
g-index

210
all docs

210
docs citations

210
times ranked

4710
citing authors

#	ARTICLE	IF	CITATIONS
1	Review and Uses of Stereotactic Body Radiation Therapy for Oligometastases. <i>Oncologist</i> , 2012, 17, 1100-1107.	1.9	185
2	Is Stereotactic Body Radiation Therapy an Attractive Option for Unresectable Liver Metastases? A Preliminary Report From a Phase 2 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 336-342.	0.4	168
3	Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). <i>Radiotherapy and Oncology</i> , 2013, 107, 414-418.	0.3	141
4	IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy. <i>Radiotherapy and Oncology</i> , 2009, 93, 207-212.	0.3	126
5	Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. <i>British Journal of Cancer</i> , 2017, 116, 1520-1525.	2.9	121
6	Linac-based VMAT radiosurgery for multiple brain lesions: comparison between a conventional multi-isocenter approach and a new dedicated mono-isocenter technique. <i>Radiation Oncology</i> , 2018, 13, 38.	1.2	117
7	Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. <i>Radiation Oncology</i> , 2011, 6, 113.	1.2	107
8	Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome and Toxicity of Stereotactic Body Radiotherapy and Elective Nodal Radiotherapy. <i>European Urology</i> , 2019, 76, 732-739.	0.9	99
9	Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: preliminary report of a phase II study. <i>Radiation Oncology</i> , 2013, 8, 171.	1.2	98
10	1.5% MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment. <i>Radiation Oncology</i> , 2020, 15, 69.	1.2	94
11	SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. <i>Radiation Oncology</i> , 2013, 8, 148.	1.2	91
12	Significant reduction of acute toxicity following pelvic irradiation with Helical Tomotherapy in patients with localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2007, 84, 164-170.	0.3	84
13	Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. <i>Radiation Oncology</i> , 2014, 9, 91.	1.2	81
14	Current status and recent advances in reirradiation of glioblastoma. <i>Radiation Oncology</i> , 2021, 16, 36.	1.2	80
15	Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients. <i>Acta Oncologica</i> , 2012, 51, 618-623.	0.8	76
16	Phase III study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments. <i>Radiation Oncology</i> , 2012, 7, 145.	1.2	72
17	Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study. <i>World Journal of Urology</i> , 2019, 37, 2631-2637.	1.2	69
18	Mastectomy or Breast-Conserving Therapy for Early Breast Cancer in Real-Life Clinical Practice: Outcome Comparison of 7565 Cases. <i>Cancers</i> , 2019, 11, 160.	1.7	68

#	ARTICLE	IF	CITATIONS
19	Stereotactic body radiation therapy for liver tumours using flattening filter free beam: dosimetric and technical considerations. <i>Radiation Oncology</i> , 2012, 7, 16.	1.2	57
20	Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy. <i>International Journal of Cardiology</i> , 2018, 255, 175-183.	0.8	57
21	Salvage therapy of intraprostatic failure after radical external-beam radiotherapy for prostate cancer: A review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 550-563.	2.0	52
22	Stereotactic body radiation therapy for abdominal targets using volumetric intensity modulated arc therapy with RapidArc: Feasibility and clinical preliminary results. <i>Acta Oncologica</i> , 2011, 50, 528-538.	0.8	51
23	Can volumetric modulated arc therapy with flattening filter free beams play a role in stereotactic body radiotherapy for liver lesions? A volume-based analysis. <i>Medical Physics</i> , 2012, 39, 1112-1118.	1.6	49
24	Will SBRT replace conventional radiotherapy in patients with low-intermediate risk prostate cancer? A review. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 101-108.	2.0	44
25	Radiotherapy in patients with connective tissue diseases. <i>Lancet Oncology</i> , The, 2016, 17, e109-e117.	5.1	42
26	The "BUONGIORNO" Project: Burnout Syndrome Among Young Italian Radiation Oncologists. <i>Cancer Investigation</i> , 2013, 31, 522-528.	0.6	41
27	Extreme hypofractionation for early prostate cancer: Biology meets technology. <i>Cancer Treatment Reviews</i> , 2016, 50, 48-60.	3.4	40
28	Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial. <i>Radiotherapy and Oncology</i> , 2019, 139, 83-86.	0.3	40
29	Linac-based radiosurgery for multiple brain metastases: Comparison between two mono-isocenter techniques with multiple non-coplanar arcs. <i>Radiotherapy and Oncology</i> , 2019, 132, 70-78.	0.3	40
30	Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. <i>Radiation Oncology</i> , 2012, 7, 204.	1.2	38
31	Volumetric-modulated arc stereotactic body radiotherapy for prostate cancer: dosimetric impact of an increased near-maximum target dose and of a rectal spacer. <i>British Journal of Radiology</i> , 2015, 88, 20140736.	1.0	38
32	Spinal metastases: Is stereotactic body radiation therapy supported by evidences?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 147-158.	2.0	37
33	ESTRO-ACROP recommendations on the clinical implementation of hybrid MR-linac systems in radiation oncology. <i>Radiotherapy and Oncology</i> , 2021, 159, 146-154.	0.3	37
34	[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 273-282.	2.6	37
35	Early clinical experience with volumetric modulated arc therapy in head and neck cancer patients. <i>Radiation Oncology</i> , 2010, 5, 93.	1.2	35
36	Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e667-e673.	0.9	35

#	ARTICLE	IF	CITATIONS
37	Large volume unresectable locally advanced non-small cell lung cancer: acute toxicity and initial outcome results with rapid arc. <i>Radiation Oncology</i> , 2010, 5, 94.	1.2	34
38	Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2020, 21, 759-760.	5.1	34
39	Modern radiotherapy in cancer treatment during pregnancy. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 136, 13-19.	2.0	33
40	Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy. <i>Acta Oncol³gica</i> , 2013, 52, 545-552.	0.8	32
41	Choline-PET in prostate cancer management: The point of view of the radiation oncologist. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 234-247.	2.0	32
42	Weekly Cisplatin and Volumetric-Modulated Arc Therapy With Simultaneous Integrated Boost for Radical Treatment of Advanced Cervical Cancer in Elderly Patients: Feasibility and Clinical Preliminary Results. <i>Technology in Cancer Research and Treatment</i> , 2017, 16, 310-315.	0.8	32
43	Phase ³ study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 113-120.	1.0	32
44	Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 24-28.	2.0	32
45	Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies. <i>Cancer Treatment Reviews</i> , 2015, 41, 511-518.	3.4	31
46	Preoperative radiotherapy: A paradigm shift in the treatment of breast cancer? A review of literature. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 141, 102-111.	2.0	31
47	Oligometastasis and local ablation in the era of systemic targeted and immunotherapy. <i>Radiation Oncology</i> , 2020, 15, 92.	1.2	31
48	Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. <i>Acta Oncol³gica</i> , 2021, 60, 215-221.	0.8	31
49	Impact of 18F-Choline PET/CT in the Decision-Making Strategy of Treatment Volumes in Definitive Prostate Cancer Volumetric Modulated Radiation Therapy. <i>Clinical Nuclear Medicine</i> , 2015, 40, e496-e500.	0.7	30
50	Synchronous bilateral breast cancer irradiation: clinical and dosimetrical issues using volumetric modulated arc therapy and simultaneous integrated boost. <i>Radiologia Medica</i> , 2017, 122, 464-471.	4.7	30
51	Impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 ⁵ T MR-guided stereotactic body radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 178.	1.2	30
52	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. <i>Cancer Treatment Reviews</i> , 2021, 98, 102206.	3.4	30
53	Optimal dose and fraction number in SBRT of lung tumours: A radiobiological analysis. <i>Physica Medica</i> , 2017, 44, 188-195.	0.4	29
54	Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a ⁵ multi-institutional analysis. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 213-221.	1.0	29

#	ARTICLE	IF	CITATIONS
55	From radiobiology to technology: what is changing in radiotherapy for prostate cancer. Expert Review of Anticancer Therapy, 2014, 14, 553-564.	1.1	28
56	Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. Medical Oncology, 2018, 35, 121.	1.2	28
57	Role of Radiosurgery/Stereotactic Radiotherapy in Oligometastatic Disease: Brain Oligometastases. Frontiers in Oncology, 2019, 9, 206.	1.3	28
58	A comparative analysis between radiation dose intensification and conventional fractionation in neoadjuvant locally advanced rectal cancer: a monocentric prospective observational study. Radiologia Medica, 2020, 125, 990-998.	4.7	28
59	Rectal spacer hydrogel in 1.5T MR-guided and daily adapted SBRT for prostate cancer: dosimetric analysis and preliminary patient-reported outcomes. British Journal of Radiology, 2021, 94, 20200848.	1.0	28
60	Dosimetric impact of inter-observer variability for 3D conformal radiotherapy and volumetric modulated arc therapy: the rectal tumor target definition case. Radiation Oncology, 2013, 8, 176.	1.2	27
61	Stereotactic radiosurgery for intracranial metastases: linac-based and gamma-dedicated unit approach. Expert Review of Anticancer Therapy, 2016, 16, 731-740.	1.1	27
62	ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial. Radiation Oncology, 2018, 13, 166.	1.2	27
63	Linac-based radiosurgery or fractionated stereotactic radiotherapy with flattening filter-free volumetric modulated arc therapy in elderly patients. Strahlentherapie Und Onkologie, 2019, 195, 218-225.	1.0	27
64	A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients. Scientific Reports, 2020, 10, 13589.	1.6	27
65	Anatomy driven optimization strategy for total marrow irradiation with a volumetric modulated arc therapy technique. Journal of Applied Clinical Medical Physics, 2012, 13, 138-147.	0.8	26
66	Hypofractionated radiotherapy in pancreatic cancer: Lessons from the past in the era of stereotactic body radiation therapy. Critical Reviews in Oncology/Hematology, 2016, 103, 49-61.	2.0	26
67	Predictors of mucositis in oropharyngeal and oral cavity cancer in patients treated with volumetric modulated radiation treatment: A dose-volume analysis. Head and Neck, 2016, 38, E815-9.	0.9	26
68	Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2547-2554.	1.2	26
69	Salvage therapy of small volume prostate cancer nodal failures: A review of the literature. Critical Reviews in Oncology/Hematology, 2014, 90, 24-35.	2.0	25
70	Whole brain radiotherapy with hippocampal avoidance and simultaneous integrated boost for brain metastases: a dosimetric volumetric-modulated arc therapy study. Radiologia Medica, 2016, 121, 60-69.	4.7	25
71	Feasibility and safety of 1.5T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2379-2397.	1.2	25
72	Current radiotherapy techniques in NSCLC: challenges and potential solutions. Expert Review of Anticancer Therapy, 2020, 20, 387-402.	1.1	24

#	ARTICLE	IF	CITATIONS
73	Is high dose rate brachytherapy reliable and effective treatment for prostate cancer patients? A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 360-370.	2.0	23
74	SBRT for prostate cancer: Challenges and features from a physicist prospective. <i>Physica Medica</i> , 2016, 32, 479-484.	0.4	23
75	Intensity-modulated radiotherapy and hypofractionated volumetric modulated arc therapy for elderly patients with breast cancer: comparison of acute and late toxicities. <i>Radiologia Medica</i> , 2019, 124, 309-314.	4.7	23
76	Could 68-Ga PSMA PET/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. <i>Radiologia Medica</i> , 2018, 123, 719-725.	4.7	22
77	Repeated stereotactic radiosurgery (SRS) using a non-coplanar mono-isocenter (HyperArc [®] , [©]) technique versus upfront whole-brain radiotherapy (WBRT): a matched-pair analysis. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 77-83.	1.7	22
78	Disease course of lung oligometastatic colorectal cancer treated with stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 813-820.	1.0	22
79	Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. <i>Anticancer Research</i> , 2013, 33, 4537-43.	0.5	22
80	An update on radiation therapy in head and neck cancers. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 359-364.	1.1	21
81	Stereotactic body radiotherapy (SBRT) can delay polymetastatic conversion in patients affected by liver oligometastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2351-2358.	1.2	21
82	MR-Guided Hypofractionated Radiotherapy: Current Emerging Data and Promising Perspectives for Localized Prostate Cancer. <i>Cancers</i> , 2021, 13, 1791.	1.7	21
83	Remission of Refractory Neurosarcoidosis Treated With Brain Radiotherapy. <i>Neurologist</i> , 2008, 14, 120-124.	0.4	20
84	Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1795-1800.	1.2	20
85	Dose variability in different lymph node levels during locoregional breast cancer irradiation: the impact of deep-inspiration breath hold. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 13-20.	1.0	20
86	Three-dimensional conformal versus intensity modulated radiotherapy in breast cancer treatment: is necessary a medical reversal?. <i>Radiologia Medica</i> , 2017, 122, 146-153.	4.7	19
87	New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming?. <i>Translational Andrology and Urology</i> , 2019, 8, S538-S541.	0.6	19
88	Adaptive SBRT by 1.5ÅT MR-linac for prostate cancer: On the accuracy of dose delivery in view of the prolonged session time. <i>Physica Medica</i> , 2020, 80, 34-41.	0.4	19
89	Stereotactic body radiotherapy for oligometastatic castration sensitive prostate cancer using 1.5ÅT MRI-Linac: preliminary data on feasibility and acute patient-reported outcomes. <i>Radiologia Medica</i> , 2021, 126, 989-997.	4.7	19
90	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. <i>Tumori</i> , 2013, 99, 637-649.	0.6	18

#	ARTICLE	IF	CITATIONS
91	Comorbidities and intensity-modulated radiotherapy with simultaneous integrated boost in elderly breast cancer patients. <i>Aging Clinical and Experimental Research</i> , 2018, 30, 533-538.	1.4	18
92	Initial Experience With Single-Isocenter Radiosurgery to Target Multiple Brain Metastases Using an Automated Treatment Planning Software: Clinical Outcomes and Optimal Target Volume Margins Strategy. <i>Advances in Radiation Oncology</i> , 2020, 5, 856-864.	0.6	18
93	The "PROCAINA (PROstate CANcer INDication Attitudes) Project" (Part II) " A survey among Italian radiation oncologists on radical radiotherapy in prostate cancer. <i>Radiologia Medica</i> , 2013, 118, 1220-1239.	4.7	17
94	Stereotactic ablative radiation therapy for brain metastases with volumetric modulated arc therapy and flattening filter free delivery: feasibility and early clinical results. <i>Radiologia Medica</i> , 2017, 122, 676-682.	4.7	17
95	Hypo-fractionated stereotactic radiation therapy for lung malignancies by means of helical tomotherapy: report of feasibility by a single-center experience. <i>Radiologia Medica</i> , 2018, 123, 406-414.	4.7	17
96	Feasibility and preliminary clinical results of linac-based Stereotactic Body Radiotherapy for spinal metastases using a dedicated contouring and planning system. <i>Radiation Oncology</i> , 2019, 14, 184.	1.2	17
97	Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18 FDG-PET/CT. <i>Journal of Thoracic Oncology</i> , 2017, 12, 547-555.	0.5	16
98	18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes. <i>Radiologia Medica</i> , 2017, 122, 952-959.	4.7	16
99	Recent Developments in Radiation Oncology: An Overview of Individualised Treatment Strategies in Breast Cancer. <i>Breast Care</i> , 2018, 13, 285-291.	0.8	16
100	The STYRO 2011 project: a survey on perceived quality of training among young Italian radiation oncologists. <i>Medical Oncology</i> , 2013, 30, 729.	1.2	15
101	Cone-beam computed tomography in lung stereotactic ablative radiation therapy: predictive parameters of early response. <i>British Journal of Radiology</i> , 2016, 89, 20160146.	1.0	15
102	Radiotherapy in patients with HIV: current issues and review of the literature. <i>Lancet Oncology</i> , The, 2017, 18, e379-e393.	5.1	15
103	Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 628-636.	1.0	15
104	Stereotactic Ablative radiation therapy (SABR) for cardiac arrhythmia: A new therapeutic option?. <i>Radiologia Medica</i> , 2021, 126, 155-162.	4.7	15
105	Mitigation on bowel loops daily variations by 1.5-T MR-guided daily-adaptive SBRT for abdomino-pelvic lymph-nodal oligometastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 3269-3277.	1.2	15
106	Personalized "Not Omitted" Radiation Oncology for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4313-4314.	0.8	14
107	Stereotactic body radiotherapy for lung oligometastases: Literature review according to PICO criteria. <i>Tumori</i> , 2018, 104, 148-156.	0.6	14
108	Stereotactic body radiotherapy of central lung malignancies using a simultaneous integrated protection approach. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 719-724.	1.0	14

#	ARTICLE	IF	CITATIONS
109	Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e187-e194.	0.9	14
110	The Impact of the SARS-CoV-2 Outbreak on the Psychological Flexibility and Behaviour of Cancelling Medical Appointments of Italian Patients with Pre-Existing Medical Condition: The "ImpACT-COVID-19 for Patients" Multi-Centre Observational Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 340.	1.2	14
111	Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience. <i>In Vivo</i> , 2018, 32, 159-164.	0.6	14
112	Initial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma. <i>Reports of Practical Oncology and Radiotherapy</i> , 2012, 17, 262-268.	0.3	13
113	Impact of surface-guided positioning on the use of portal imaging and initial set-up duration in breast cancer patients. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 964-971.	1.0	13
114	Deep inspiration breath-hold intensity modulated radiation therapy in a large clinical series of 239 left-sided breast cancer patients: a dosimetric analysis of organs at risk doses and clinical feasibility from a single center experience. <i>British Journal of Radiology</i> , 2019, 92, 20190150.	1.0	13
115	Stereotactic radiosurgery for patients with brain metastases. <i>Lancet Oncology</i> , The, 2014, 15, e246-e247.	5.1	12
116	SBRT and extreme hypofractionation: A new era in prostate cancer treatments?. <i>Reports of Practical Oncology and Radiotherapy</i> , 2015, 20, 411-416.	0.3	12
117	Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 117, 48-56.	2.0	12
118	The Role of Stereotactic Ablative Radiotherapy in Oncological and Non-Oncological Clinical Settings: Highlights from the 7 th Meeting of AIRO "Young Members Working Group (AIRO Giovani)". <i>Tumori</i> , 2014, 100, e214-e229.	0.6	12
119	A strategy for young members within national radiation oncology societies: the Italian experience (AIRO Giovani group). <i>Reports of Practical Oncology and Radiotherapy</i> , 2012, 17, 259-261.	0.3	11
120	What is the role of [11C]choline PET/CT in decision making strategy before post-operative salvage radiation therapy in prostate cancer patients?. <i>Acta Oncologica</i> , 2014, 53, 990-992.	0.8	11
121	The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, e501-e510.	1.1	11
122	Prostate re-irradiation: current concerns and future perspectives. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 947-956.	1.1	11
123	1.5T MR-Guided Daily Adaptive Stereotactic Body Radiotherapy for Prostate Re-Irradiation: A Preliminary Report of Toxicity and Clinical Outcomes. <i>Frontiers in Oncology</i> , 2022, 12, 858740.	1.3	11
124	Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after Neoadjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). <i>BMC Cancer</i> , 2019, 19, 1215.	1.1	10
125	Combination of novel systemic agents and radiotherapy for solid tumors " Part II: An AIRO (Italian) Tj ETQq1 1 0.784314 rgBT /Overl Reviews in Oncology/Hematology, 2019, 134, 104-119.	2.0	10
126	An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation. <i>Radiotherapy and Oncology</i> , 2021, 164, 104-114.	0.3	10

#	ARTICLE	IF	CITATIONS
127	Letter. Neurosurgery, 2015, 77, E310.	0.6	9
128	Dosimetrics of intracranial stereotactic radiosurgery. Strahlentherapie Und Onkologie, 2015, 191, 810-811.	1.0	9
129	A national multicenter study on 1072 DCIS patients treated with breast-conserving surgery and whole breast radiotherapy (COBCG-01 study). Radiotherapy and Oncology, 2019, 131, 208-214.	0.3	9
130	Two months of radiation oncology in the heart of Italian "covered zone" during COVID-19 pandemic: paving a safe path over thin ice. Radiation Oncology, 2020, 15, 191.	1.2	9
131	PROLAPSE: survey about local prostate cancer relapse salvage treatment with external beam re-irradiation: results of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Journal of Cancer Research and Clinical Oncology, 2020, 146, 2311-2317.	1.2	9
132	Letter to the Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during COVID-19 pandemic. Radiotherapy and Oncology, 2020, 147, 229-230.	0.3	9
133	The role of postoperative radiotherapy for thymomas: a multicentric retrospective evaluation from three Italian centers and review of the literature. Journal of Thoracic Disease, 2020, 12, 7518-7530.	0.6	9
134	Impact of radiation therapy on pain relief of cancer patients affected by on malignant psoas syndrome: 26 years of experience. Indian Journal of Palliative Care, 2020, 26, 348.	1.0	9
135	Toxicity of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: A Potential Comparison Bias. Journal of Clinical Oncology, 2014, 32, 3454-3454.	0.8	8
136	Low-Dose Bath with Volumetric Modulated arc Therapy in Breast Cancer: "Much ado about Nothing?". Tumori, 2016, 102, 335-336.	0.6	8
137	Hippocampal dose during Linac-based stereotactic radiotherapy for brain metastases: An observational study. Physica Medica, 2018, 49, 135-138.	0.4	8
138	Cost-effectiveness of Linac-based single-isocenter non-coplanar technique (HyperArcTM) for brain metastases radiosurgery. Clinical and Experimental Metastasis, 2018, 35, 601-603.	1.7	8
139	Moderate hypofractionated helical tomotherapy for localized prostate cancer: preliminary report of an observational prospective study. Tumori, 2019, 105, 516-523.	0.6	8
140	Hypofractionated radiation therapy in the management of locally advanced NSCLC: a narrative review of the literature on behalf of the Italian Association of Radiation Oncology (AIRO) "Lung Working Group. Radiologia Medica, 2019, 124, 136-144.	4.7	8
141	Post-HIFU locally relapsed prostate cancer: high-dose salvage radiotherapy guided by molecular imaging. Radiologia Medica, 2020, 125, 491-499.	4.7	8
142	PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients. Radiologia Medica, 2021, 126, 460-465.	4.7	8
143	The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. Clinical Lung Cancer, 2021, 22, e767-e773.	1.1	8
144	Combination of novel systemic agents and radiotherapy for solid tumors " part I: An AIRO (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 TF 5 Reviews in Oncology/Hematology, 2019, 134, 87-103.	2.0	7

#	ARTICLE	IF	CITATIONS
145	MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. <i>Journal of Clinical Pathology</i> , 2022, 75, 39-44.	1.0	7
146	First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2022, 22, 50-54.	0.6	7
147	Stereotactic ablative radiotherapy in patients with refractory ventricular tachyarrhythmia. <i>European Heart Journal Supplements</i> , 2022, 24, C248-C253.	0.0	7
148	¹⁸ F-Sodium Fluoride PET-CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e67-e68.	0.5	6
149	Simultaneous Integrated Bilateral Breast and Nodal Irradiation with Volumetric arc Therapy: Case Report and Literature Review. <i>Tumori</i> , 2016, 102, S32-S34.	0.6	6
150	The Pocketable Electronic Devices in Radiation Oncology (PEDRO) Project. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 365-376.	0.8	6
151	Combinatorial Effect of Magnetic Field and Radiotherapy in PDAC Organoids: A Pilot Study. <i>Biomedicines</i> , 2020, 8, 609.	1.4	6
152	Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance. <i>Medical Oncology</i> , 2021, 38, 72.	1.2	6
153	Postoperative Breast Radiotherapy after Neoadjuvant Chemotherapy: Which Uncertainties still Remain?. <i>Tumori</i> , 2014, 100, e212-e213.	0.6	6
154	Reduction of inter-observer differences in the delineation of the target in spinal metastases SBRT using an automatic contouring dedicated system. <i>Radiation Oncology</i> , 2021, 16, 197.	1.2	6
155	Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2940-2941.	0.8	5
156	Non-palliative radiotherapy in ab initio oligometastatic prostate cancer: an Italian national survey. <i>Radiologia Medica</i> , 2019, 124, 211-217.	4.7	5
157	Reply to Ghaffari et al. In regard to Cuccia et al.: impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5T MR-guided stereotactic body radiotherapy. <i>Radiation Oncology</i> , 2020, 15, 213.	1.2	5
158	Intra-fraction and Inter-fraction analysis of a dedicated immobilization device for intracranial radiation treatment. <i>Radiation Oncology</i> , 2020, 15, 200.	1.2	5
159	Repeated stereotactic radiosurgery for the treatment of relapsed brain metastases: is it time to give up whole-brain radiotherapy?. <i>Oncoscience</i> , 2020, 7, 19-20.	0.9	5
160	Consolidative local therapy in oligometastatic patients. <i>Lancet Oncology</i> , The, 2017, 18, e60.	5.1	4
161	Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?. <i>British Journal of Radiology</i> , 2019, 92, 20181026.	1.0	4
162	What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?. <i>Lung Cancer</i> , 2020, 146, 263-275.	0.9	4

#	ARTICLE	IF	CITATIONS
163	The role of radiotherapy in patients with solid tumours after solid organ transplantation: a systematic review. <i>Lancet Oncology</i> , The, 2021, 22, e93-e104.	5.1	4
164	OLIGO-AIRO: a national survey on the role of radiation oncologist in the management of OLIGO-metastatic patients on the behalf of AIRO. <i>Medical Oncology</i> , 2021, 38, 48.	1.2	4
165	Cutaneous soft tissue sarcomas: survival-related factors. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	4
166	PSMA-guided metastases directed therapy for bone castration sensitive oligometastatic prostate cancer: a multi-institutional study. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 443.	1.7	4
167	Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: No Way Out Without a Randomized Trial?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2558-2559.	0.8	3
168	Dose prescription in SBRT for early-stage non-small cell lung cancer: are we all speaking the same language?. <i>Tumori</i> , 2021, 107, 030089162092942.	0.6	3
169	Radiotherapy activities and technological equipment in Veneto, Italy: a report from the Rete Radioterapica Veneta. <i>Radiologia Medica</i> , 2021, 126, 623-629.	4.7	3
170	In reply to Fiorino et al.: The central role of the radiation oncologist in the multidisciplinary & multiprofessional model of modern radiation therapy. <i>Radiotherapy and Oncology</i> , 2021, 155, e20-e21.	0.3	3
171	Impact of hydrogel peri-rectal spacer insertion on seminal vesicles intrafraction motion during 1.5T-MRI-guided adaptive stereotactic body radiotherapy for localized prostate cancer. <i>British Journal of Radiology</i> , 2021, 94, 20210521.	1.0	3
172	Could Single-high-dose Radiotherapy be Considered the New Frontier of Stereotactic Ablative Radiation Therapy?. <i>Tumori</i> , 2014, 100, e92-e93.	0.6	3
173	Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy. <i>Radiologia Medica</i> , 2022, , 1.	4.7	3
174	Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 727.	1.1	3
175	In Regard to Boero et Al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 855-856.	0.4	2
176	A Plethora of Therapeutic Opportunities for Elderly Patients With Cancer: A Nontrivial Choice. <i>Journal of Clinical Oncology</i> , 2016, 34, 1963-1964.	0.8	2
177	Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088). <i>Trials</i> , 2020, 21, 678.	0.7	2
178	Reply to: The course of lung oligometastatic colorectal cancer may be a reflection of selection for treatment rather than an effect of stereotactic body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 76-78.	1.0	2
179	Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 391-396.	0.7	2
180	The Impact of Different Timing Schedules on Prostate HDR-Mono-Brachytherapy. A TCP Modeling Investigation. <i>Cancers</i> , 2021, 13, 4899.	1.7	2

#	ARTICLE	IF	CITATIONS
181	Could single-high-dose radiotherapy be considered the new frontier of stereotactic ablative radiation therapy?. Tumori, 2014, 100, e92-3.	0.6	2
182	Benign Intracranial Lesions - Radiotherapy: An Overview of Treatment Options, Indications and Therapeutic Results. Reviews on Recent Clinical Trials, 2020, 15, 93-121.	0.4	2
183	Watch-and-wait versus surgical resection for patients with rectal cancer. Lancet Oncology, The, 2016, 17, e133-e134.	5.1	1
184	In Regard to Kubicek etÂal. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1318-1319.	0.4	1
185	Daily IGRT for prostate cancer: Can we stop the train?. Radiotherapy and Oncology, 2018, 128, 389-390.	0.3	1
186	In reply to Simcock et al.. Clinical and Translational Radiation Oncology, 2020, 23, 65.	0.9	1
187	Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. Future Oncology, 2021, 17, 807-815.	1.1	1
188	Radiation-Induced Oral Mucositis in Head and Neck Cancer Patients. Five Years Literature Review. Reviews on Recent Clinical Trials, 2021, 16, 151-165.	0.4	1
189	RR Myelo POINT: A Retrospective Single-Center Study Assessing the Role of Radiotherapy in the Management of Multiple Myeloma and Possible Interactions with Concurrent Systemic Treatment. Cancers, 2022, 14, 2273.	1.7	1
190	In Response to Dr. Russi and Colleagues. International Journal of Radiation Oncology Biology Physics, 2011, 79, 1279-1280.	0.4	0
191	Relationship Between Molecular Oncology and Radiotherapy in Malignant Gliomas (An Overview). , 2012, , 103-110.		0
192	Solitary Brain Metastasis from Non-Small Cell Lung Cancer. , 2014, , 131-139.		0
193	In Regard to Chung etÂal. International Journal of Radiation Oncology Biology Physics, 2015, 93, 941-942.	0.4	0
194	Re: Daniel E. Spratt, Hebert A. Vargas, Zachary S. Zumsteg, et al. Patterns of Lymph Node Failure after Dose-escalated Radiotherapy: Implications for Extended Pelvic Lymph Node Coverage. Eur Urol 2017;71:37â€“43. European Urology, 2017, 71, e121-e122.	0.9	0
195	Stereotactic precision and conventional radiotherapy evaluation (SPACE)-Trial for medically inoperable Stage I NSCLC: A lost opportunity?. Radiotherapy and Oncology, 2017, 122, 319.	0.3	0
196	Induction chemotherapy for nasopharyngeal cancer: AnÂeternally unfinished issue?. European Journal of Cancer, 2017, 82, 153-154.	1.3	0
197	Reply to â€“Comment on â€“Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric studyâ€™â€™. British Journal of Cancer, 2018, 118, e2-e2.	2.9	0
198	Sparing of swallowing-related organs in radiotherapy for oropharyngeal squamous cell carcinoma. Lancet Oncology, The, 2019, 20, e611.	5.1	0

#	ARTICLE	IF	CITATIONS
199	Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel. <i>ESMO Open</i> , 2020, 5, e000696.	2.0	0
200	Standard (8 weeks) vs long (12 weeks) Timing to Minimally-Invasive Surgery after NeoAdjuvant Chemoradiotherapy for Rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR). <i>European Journal of Surgical Oncology</i> , 2020, 46, e89-e90.	0.5	0
201	Honey Against Radiation-induced Oral Mucositis in Head and Neck Cancer Patients. An Umbrella Review of Systematic Reviews and Meta- Analyses of the Literature. <i>Reviews on Recent Clinical Trials</i> , 2021, 15, 360-369.	0.4	0
202	Metastasis Directed Therapy and/or Systemic Therapy in Hormone-naive Oligometastatic Prostate Cancer Patient: an Emerging Dilemma. <i>Journal of Medical & Radiation Oncology</i> , 2021, 1, 139-144.	0.0	0
203	Salvage local treatment for localized radio-recurrent prostate cancer: a narrative review and future perspectives. <i>Future Oncology</i> , 2021, 17, 4207-4219.	1.1	0
204	Multimodality imaging for early assessment of head and neck patients during induction chemotherapy: a reliable future option?. <i>Translational Cancer Research</i> , 2016, 5, S405-S407.	0.4	0
205	Using Imaging to Design Dose Volume Constraints for Target and Normal Tissue to Reduce Toxicity. , 2019, , 75-83.		0
206	Reply to: Stereotactic radiotherapy needs more evidence before it can be used routinely to treat metastases: a comment on the paper by Nicosia et al. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0
207	A novel treatment for malignant spasticity: The therapeutic use of stereotactic radiosurgery (SRS). <i>Radiotherapy and Oncology</i> , 2022, 169, 86-89.	0.3	0